Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023


Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update.

To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4844622. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. In June 2023, Seres was named one of the TIME100 Most Influential Companies. Seres' lead program, VOWSTtm, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.


These press releases may also interest you

at 04:09
CGTN: China, Kazakhstan cherish friendly ties, vow further cooperation
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...

at 04:05
H.I.G. Capital Signs Definitive Agreement to Acquire CGH Group
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $64 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire CGH Group S.A. ("CGH" or the "Company"), a...

at 03:55
INC Unveils Gen Z Preferences for Nuts and Dried Fruits and Snacking in Latin America
The International Nut and Dried Fruit Council (INC), conducted an extensive study on Latin America's Gen Z dietary...

at 03:44
Invitation to presentation of the interim report January-June 2024 for Truecaller AB (publ)
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-June on Friday 19 July 2024 at 07.30 CET.  Alan Mamedi, CEO and Odd Bolin, CFO presents the report and...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:09
CGTN: China, Kazakhstan cherish friendly ties, vow further cooperation
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...

More news about Science and technology...


News published on and distributed by: